

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No 05-967-A5; (EX04-058C-US))**

In the Application of:)	
)	
Francis-Lang <i>et al.</i>)	
)	Examiner: Yao, Lei
Serial No.: 10/568,253)	
)	Group Art Unit: 1642
Filing Date: June 2, 2006)	
)	Confirmation No. 4136
For: UPs as Modifiers of the Beta-Catenin)	
Pathway and Methods of Use)	

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on May 1, 2008 in the above-mentioned application. It is believed that no fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicant hereby elects with traverse Group III, claims 1 and 8-10, allegedly drawn to an *in vitro* method of identifying a candidate beta catenin pathway modulating agent comprising providing an assay system comprising a UP nucleic acid, wherein the candidate beta catenin pathway modulating agent is an antisense oligomer, for prosecution on the merits. The claims readable thereon are claims 1 and 8-10.

If the Examiner has any questions regarding this response, he is invited to call the undersigned attorney at 312-913-0001.

Respectfully submitted,

Dated: June 2, 2008

/Sherri L. Oslick/
Sherri L. Oslick, Ph.D.
Registration No. 52,087